An extroverted pathologist, podcaster, yoga enthusiast, BollyX instructor..and a classic ENFP!!! #cytopath #pathology
Cleveland, OH
Joined September 2009
- Tweets590
- Following554
- Followers633
- Likes1.2K
Rema (Rao) Chaari retweeted
Pathology fact of the day #pfotd
90% of carcinoid tumors ("NET") of the lung are "typical" and only 10% of these recur. In other words, the prognosis in most carcinoid tumors is very good
What happened to the #pfotd
It is a brilliant idea....it seems that it needs refreshing to keep going.
Come on dear colleagues.share your #pfotd @ariella8 @DrGeeONE @DrMarkOng @DrRanasaleh @Dr_Brian_Cox @atman_ci @PoloniaAntonio @drtimbracey @kriyer68 @SumantaDas_7 @Chucktowndoc
Rema (Rao) Chaari retweeted
🎥 In this #CytoVideo, @tarik_elsheikh explains how correlation of AUS, AUS:M, and ROM with molecular results can offer a robust framework for QA.
🔗 #OpenAccess article: acsjournals.onlinelibrary.wi…
🔗 Full video: youtube.com/watch?v=2SI3mzIB…
@CLEClinicLabs @CleClinicMD @Raodyisms
Rema (Rao) Chaari retweeted
Less than 4 weeks to our 3rd annual Cleveland Clinic Soft Tissue Pathology Course May 14-17!!! 150 NEW digital cases in an interactive slide-based format. In person and VIRTUAL option. Lectures available on demand for at least 6 months!!! Register now!!! na01.safelinks.protection.ou… @Williamson_SR @RAlaghehbandan @Janiranavarro @JaneNguyen44 @ScottBikeethan @CCFPathRes @CLEClinicLabs #bst #pathtwitter #path #softtissue
Rema (Rao) Chaari retweeted
It is never too early to begin planning for your next conference, January 2027. This will be a general surgical pathology conference, but I also will make sure we talk about bone/soft tissue pathology (@SteveBillingsMD too!). @CCFPathRes @CLEClinicLabs
pathologyoutlines.com/confer…
The “illusion of continuity” — assuming your future self wants what you want today — shapes how we lead, teach, and grow in ways we rarely examine.
Shankar Vedantam’s TED talk is a quiet reframe worth 14 minutes.
t.ted.com/mzYn5VM
Rema (Rao) Chaari retweeted
majority of tumors in our classification system were described and well documented prior to being also confirmed as having molecular drivers. For sure, molecular testing has helped clarify boundaries, but the classification system has expanded not contracted, with only a
Rema (Rao) Chaari retweeted
🎥 In this #CytoVideo, @tarik_elsheikh explains how correlation of AUS, AUS:M, and ROM with molecular results can offer a robust framework for QA.
🔗 #OpenAccess article: acsjournals.onlinelibrary.wi…
🔗 Full video: youtu.be/2SI3mzIBULg
@CLEClinicLabs @CleClinicMD @Raodyisms
Rema (Rao) Chaari retweeted
New and #OpenAccess! | Molecular testing and other metrics in thyroid cytology as quality-assurance measures in evaluating variation among pathologists in the diagnosis of atypia of undetermined significance
acsjournals.onlinelibrary.wi…
#CytoPath @Raodyisms @erikacytogal @ENT_Path
Rema (Rao) Chaari retweeted
Congratulations to @elsheikhtarik and @Raodyisms for their comprehensive look at #QA in #thyroid #cytology. In case of #TLDR, see Table 3 to see how *your* lab compares! @GokozanMD @MichiyaNishino @CancerCytopath acsjournals.onlinelibrary.wi…
Rema (Rao) Chaari retweeted
Outstanding grand rounds by @KMirza on the virtual renaissance of pathology education at @CCFPathRes 👏👏👏
#PathX #PathTwitter
Rema (Rao) Chaari retweeted
This review covers all relevant aspects of #telecytology for ROSE, including digital pathology options, operators, validation, quality assurance, reimbursement, and recommendations from professional organizations. 🌹
acsjournals.onlinelibrary.wi…
@MDAndersonNews #CytoPath
Rema (Rao) Chaari retweeted
📊 The Area Under the Curve (AUC) is a single number that shows how well a model can tell categories apart. It combines sensitivity (finding true positives) and specificity (avoiding false positives) into one overall score. A perfect model has an AUC of 1.0—no missed diagnoses, no false alarms. The higher the AUC, the more accurate and reliable the model is across all threshold settings. Think of it as the model’s “diagnostic precision” score!
Rema (Rao) Chaari retweeted
If you decide to seek a second opinion for a life altering diagnosis, I highly recommend that you have your original pathology diagnosis, when applicable, also reviewed. At many institutions this is (and should be) standard practice.
Rema (Rao) Chaari retweeted
PIRO is very cool, developed by Scott and used by many in our department. Please check it out!
We built a fast web-based application for searching pathology reports. Works especially well with Epic data. Contact me if you want to learn more. #Pathology
Manuscript Link:
doi.org/10.1016/j.jpi.2025.1…
Rema (Rao) Chaari retweeted
We built a fast web-based application for searching pathology reports. Works especially well with Epic data. Contact me if you want to learn more. #Pathology
Manuscript Link:
doi.org/10.1016/j.jpi.2025.1…
Rema (Rao) Chaari retweeted
Crucial to this approach is vastly overstating the value of NGS and targeted therapy. How many low grade neoplasms with a fusion do we need and how does it help the patient when they are all treated exactly the same?
Rema (Rao) Chaari retweeted
Very true—but patients are aspirational, and so are their clinicians. People want the best, and the WHO has positioned itself as the gold standard in tumor classification.
I’ve seen families willing to spend a lifetime’s savings on a single genetic test, just to give their child a shot at the best treatment. That’s how much weight the WHO carries.
Which is why it’s deeply troubling that so much of its current framework is based on low-quality evidence and personal opinion. That’s not just poor science—it’s unfair.